Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04976530 · ClinicalTrials.gov registry record · NA
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
A NA study, sponsored by CytoSorbents.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT04976530 is a NA study that has completed, run by CytoSorbents. The registered enrollment target is 140 participants.
The verdict
NCT04976530, a NA study, has completed, sponsored by CytoSorbents.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent cardiothoracic (CT) surgery with cardiopulmonary bypass (CPB).
Interventions
- DEVICE Sham comparator
- DEVICE DrugSorb-ATR system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2023-08-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04976530
The ClinicalTrials.gov registry entry for NCT04976530 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoSorbents, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham comparator is the first listed.
NCT04976530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04976530 about?
NCT04976530 is a clinical study titled "Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)". Prospective, multi-center, double-blind, randomized pivotal trial to evaluate the safety and effectiveness of the DrugSorb-Antithrombotic Removal (ATR) system for intraoperative removal of ticagrelor in patients undergoing urgent cardiothoracic (CT) surgery with cardiopulmonary bypass (CPB).
What is the current status of trial NCT04976530?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2021-08-31. Estimated completion is 2023-08-07.
What interventions are being tested in trial NCT04976530?
The interventions under investigation include: Sham comparator (DEVICE), DrugSorb-ATR system (DEVICE).
Who is sponsoring clinical trial NCT04976530?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.